Theranos Inc., the once-revered Silicon Valley medical startup, plans to challenge the revocation of its license to operate a California lab, among other sanctions federal regulators in Washington imposed after finding lax blood-testing practices.
In a statement released late Thursday, the company said it had filed a notice of intent to appeal the July decision. Still, Theranos said it hopes to keep settlement negotiations open with the Centers for Medicare and Medicaid Services, which regulates U.S. labs.
